Reduction in Herpes Zoster Antiviral Use Since the Introduction of the Live-Attenuated Zoster Vaccine on Australia’s National Immunisation Program: A Population-Based Study from 1994 to 2019
Abstract Introduction Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are limited data characterising the incidence of HZ at the...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Adis, Springer Healthcare
2023-01-01
|
| シリーズ: | Infectious Diseases and Therapy |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1007/s40121-022-00749-y |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|